Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP2B6*6 allele and age substantially reduce steady-state ketamine clearance in chronic pain patients: impact on adverse effects.

British journal of clinical pharmacology - 1 Aug 2015

Li Yibai, Jackson Kate A, Slon Barry, Hardy Janet R, Franco Michael, William Leeroy, Poon Peter, Coller Janet K, Hutchinson Mark R, Currow David C, Somogyi Andrew A

Abstract excerpt

AIMS: Ketamine analgesia is limited by low intrinsic efficacy compounded by large interindividual variability in drug responses, possibly due to the heterogeneity in drug concentration. The CYP2B6*6 allele is associated with substantially reduced ketamine metabolism in vitro and, therefore, may affect ketamine clearance. Our aims were to examine the impact of the CYP2B6*6 allele on ketamine plasma clearance and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Analgesics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chronic Pain

Share to Cytochrome P-450 CYP2B6

Share to Double-Blind Method

Share to Linear Models

Share to Metabolic Clearance Rate

Source

Open in PubMed Open full text

Identifiers

PMID: 25702819
DOI: 10.1111/bcp.12614
PMCID: PMC4541975

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP2B6*6 allele and age substantially reduce steady-state ketamine clearance in chronic pain patients: impact on adverse effects.PMID 25702819Read ↗

The CYP2B6*6 allele significantly alters the N-demethylation of ketamine enantiomers in vitro.Semantic proximity Read ↗

Methadone Pharmacogenetics: CYP2B6 Polymorphisms Determine Plasma Concentrations, Clearance, and Metabolism.Semantic proximity Read ↗

Pharmacogenomics of commonly used intravenous anesthetics.Semantic proximity Read ↗

Impact of clinical factors and UGT1A9 and CYP2B6 genotype on inter-individual differences in propofol pharmacokinetics.Semantic proximity Read ↗

Influence of CYP2D6 phenotype on the pharmacokinetics and pharmacodynamics of tramadol in patients treated for post-operative pain management.Semantic proximity Read ↗

Stereoselective Ketamine Metabolism by Genetic Variants of Cytochrome P450 CYP2B6 and Cytochrome P450 Oxidoreductase.Semantic proximity Read ↗

Novel associations between CYP2B6 polymorphisms, perioperative methadone metabolism and clinical outcomes in children.Semantic proximity Read ↗

CYP2A6 genetic variation and dexmedetomidine disposition.Semantic proximity Read ↗

Impact of CYP2D6 and CYP2B6 phenotypes on the response to tramadol in patients with acute post-surgical pain.Semantic proximity Read ↗

Distribution of CYP2D6 multiplication, CYP2D6*5, and clinical implications in postoperative patients receiving tramadol analgesia in the Minangkabau ethnic group, IndonesiaSemantic proximity Read ↗

Insights into CYP2B6-mediated drug–drug interactionsSemantic proximity Read ↗

CYP2D6 genotype dependent oxycodone metabolism in postoperative patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.